Prognostic Biomarkers in Early-Stage B-CLL Patients

1. Martinelli S, CuneoA, Formigaro L, Cavallari M, Lista E, Quaglia MF, et al. Identifying high-risk chronic lymphocytic leukemia: a pathogenesis- oriented appraisal of prognostic and predictive factors in patients treated with chemotherapy with or without immunotherapy. Mediterr J Hematol Infect Dis. 2016;8(1):e2016047.10.4084/mjhid.2016.047511152527872727Search in Google Scholar

2. Montserat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program, 2006;279-84.10.1182/asheducation-2006.1.27917124073Search in Google Scholar

3. Bernier GM. beta 2-Microglobulin: structure, function and significance. Vox Sang.1980;38(6):323-7.Search in Google Scholar

4. Berrebi A, Shvidel L, Arditti D F, Bassous L, Haran M, Shtalrid M. The Significance of elevated beta 2-Microglobulin (b2-m) in B-CLL: evidence of in vitro b2-m secretion following activation of B-CLL cells. Blood. 2009; 114:4380.10.1182/blood.V114.22.4380.4380Search in Google Scholar

5. Argyropoulos CP, Chen SS, Ng Y-H, Roumelioti ME, Kamran S, Singh PP, et al. Rediscovering beta-2 Microglobulin as a biomarker across the spectrum of kidney diseases. Front Med (Lausanne). 2017;4:73.10.3389/fmed.2017.00073547131228664159Search in Google Scholar

6. Bethea M, Forman D. Beta -microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990;20(3):163-8.Search in Google Scholar

7. Andreucci M, Faga T, Riccio E, Sabbatini M, Pisani A, Michael A. The potential use of biomarkers in predicting contrast-induced acute kidney injury.Int J Nephrol Renovasc Dis. 2016; 9:205-21.10.2147/IJNRD.S105124502477727672338Search in Google Scholar

8. Zeng X, Hossain D, Bostwick DG, Herrera GA, Ballester B, Zhang PL. Urinary β2- microglobulin is a sensitive indicator for renal tubular injury. Scholarena Journal (SAJ) of Case Reports. 2014;1(1):1-6:10.18875/2375-7043.1.103Search in Google Scholar

9. Jimenez-Zepeda VH, Duggan P, Neri P, Rashid- Kolvear F, Tay J, Bahlis NJ. Revised International Staging System applied to real world multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2016;16(9):511–8.10.1016/j.clml.2016.06.00127425179Search in Google Scholar

10. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, et al. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-Rituximab vs CHOP + ¹³¹Iodine-Tositumomab. Clin Cancer Res. 2013 Dec; 19(23).10.1158/1078-0432.CCR-13-1120387205224130072Search in Google Scholar

11. Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Poeta GD, et al. Functional and clinical significance of the lntegrin Alpha Chain CD49d expression in chronic lymphocytic leukemia. Curr Cancer Drug Targets. 2016;16(8):659-68.10.2174/156800961666616080910221927514846Search in Google Scholar

12. Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, et al. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia. 2012;26(6):1301-12.10.1038/leu.2011.36922289918Search in Google Scholar

13. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J. Clin. Oncol. 2014;32(9):897-904.Search in Google Scholar

14. Gentile M, Cutrona G, Neri A, Molica S, Ferrarini M, Morabito F. Predictive value of β2-microglobulin (β2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematolica. 2009; 94(6):887-8.10.3324/haematol.2009.005561268858519483161Search in Google Scholar

15. Sarris K, Maltezas D, Koulieris E, Bartzis V, Tzenou T, Sachanas S, et al. Prognostic significance of serum free light chains in chronic lymphocytic leukemia. Clin Adv Hematol. Oncol. 2013 Oct 29;ID 359071.10.1155/2013/359071383076024288537Search in Google Scholar

16. Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Rozman M, Aymerich M, et al. CD49d (lTGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukemia and mutated IGHV status. Br J Haematol. 2016;172(1):48-55.10.1111/bjh.1378826559905Search in Google Scholar